Definium’s LSD Pill Clears Second Phase 3 Trial
Definium’s DT120 hit its primary endpoint in a Phase 3 anxiety trial, marking the psychedelics developer’s second late-stage win in two months.
A Second Pivotal Win in Two Months
Definium Therapeutics has reported positive topline results from Voyage, its first Phase 3 trial of DT120, a pharmaceutical-grade, orally disintegrating tablet form of LSD, in adults with generalized anxiety disorder. The 214-patient study met its primary endpoint and all key secondary endpoints, with treated patients showing an average 11.6-point reduction on the Hamilton Anxiety Rating Scale at week 12, compared with a 6.2-point reduction in the placebo arm. That 5.4-point placebo-adjusted separation came in above the roughly five-point improvement analysts had been modeling heading into the readout, and reflected a large statistical effect size.
The result is Definium’s second consecutive Phase 3 success in as many months, following positive data in June from a separate trial testing the same drug in major depressive disorder. Together, the two readouts give Definium’s single-dose LSD formulation confirmed pivotal-stage efficacy across two of the largest markets in psychiatry, both built around long-standing SSRI and SNRI drug classes that DT120’s mechanism sits entirely outside of.
How the Study Was Designed and What It Found
Voyage randomized patients to receive a single 100-microgram dose of DT120 or placebo, then tracked anxiety symptoms using the 56-item Hamilton Anxiety Rating Scale, which captures the emotional, cognitive, and physical dimensions of generalized anxiety, including worry, sleep disruption, and physical symptoms like muscle tension and nausea. Benefits were apparent within days of dosing and were sustained through the full 12-week assessment period. The trial builds on earlier Phase 2b data establishing a dose-response relationship for DT120, from which the 100-microgram dose used in Voyage was selected.
The safety profile was consistent with the company’s prior clinical experience, and the trial identified no new signals, including no indication of increased suicidal thoughts or behavior. Patients are monitored for up to eight hours after dosing using an end-of-session checklist that assesses psychological and physical state; the median time to meet that checklist in the initial study cohort was 6.4 hours, and 92% of participants had met the criteria by the eight-hour mark.
Analyst and Market Reaction
Wall Street’s response was swift and largely positive. Shares of Definium jumped as much as 18% in early trading, before settling to a more modest but still meaningful gain by mid-morning. Sell-side analysts described the data in similarly strong terms, with one calling it a clean win and pointing to durability and consistency with earlier trial results as reasons for confidence. Peak sales estimates for DT120 across its studied indications now range as high as several billion dollars combined, with individual analysts modeling roughly $1.5 billion to $2 billion in major depression alone and comparable multibillion-dollar peak sales estimates layered on top for generalized anxiety and a planned post-traumatic stress disorder program.
Definium’s chief executive characterized the placebo-adjusted improvement as unusually large for a pivotal anxiety study, and argued the results should reset expectations for what a single-dose GAD treatment can achieve. The company enters this stage of development from a position of financial strength, having reported roughly $1.1 billion in cash and investments as of the end of June, aided by a public offering that raised close to $758 million earlier this year.
What’s Next
Voyage is the first of two pivotal Phase 3 trials Definium is running in generalized anxiety disorder. A second trial, Panorama, adds a low-dose comparator arm intended to help control for functional unblinding, since patients who feel psychoactive effects can often guess they’ve received active drug rather than placebo. Data from Panorama are expected in September, and a positive result would support a regulatory filing covering both anxiety and depression indications. Beyond the current programs, Definium expects high-level results from an additional major depression study next year and plans to start a late-stage trial in post-traumatic stress disorder around the same time. DT120 has also received FDA Breakthrough Therapy designation for generalized anxiety disorder.
Buyer and Procurement Implications
For payers, health systems, and specialty pharmacy networks tracking the psychedelics pipeline, DT120’s back-to-back Phase 3 wins move the drug from a speculative asset to a near-term formulary and reimbursement planning question. The single-dose, in-clinic administration model, requiring monitored dosing sessions rather than a take-home prescription, has different site-of-care and billing implications than standard oral psychiatric medications, and health systems building capacity for it should plan around monitored administration infrastructure rather than typical outpatient pharmacy dispensing. Given the mechanism’s departure from existing SSRI and SNRI classes, formulary committees may also want to begin scoping utilization criteria ahead of a potential approval, particularly since the company is pursuing rapid label expansion across multiple high-prevalence psychiatric indications rather than a single narrow indication.
FAQ
What condition did Definium’s most recent Phase 3 trial target?
The Voyage trial tested DT120, an LSD-based orally disintegrating tablet, in adults with generalized anxiety disorder, and met its primary endpoint with a statistically significant reduction in anxiety symptoms compared with placebo.
How does DT120 compare with existing anxiety medications?
Unlike SSRIs and SNRIs, the current standard treatments for generalized anxiety disorder, DT120 is a serotonin 5-HT2A receptor partial agonist administered as a single monitored dose rather than a daily oral medication.
What safety concerns emerged from the trial?
The study reported no new safety signals and no evidence of increased suicidal thoughts or behavior, with a safety profile consistent with the company’s earlier clinical experience with the drug.
Sources
- BioPharma Dive, “Psychedelics developer Definium scores more positive data for LSD pill” — https://www.biopharmadive.com/news/definium-lsd-psychedelics-trial-results-gad-anxiety/827669/
- Psychiatric Times, “DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial” — https://www.psychiatrictimes.com/view/dt120-lysergide-shows-rapid-lasting-relief-for-generalized-anxiety-in-phase-3-trial
- Fierce Biotech, “Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety” — https://www.fiercebiotech.com/biotech/definium-hits-another-ph-3-homerun-psychedelic-sea-change-anxiety
- Clinical Trial Vanguard, “Definium’s DT120 Meets Primary Endpoint in Phase 3 Anxiety Trial” — https://www.clinicaltrialvanguard.com/news/definiums-dt120-meets-primary-endpoint-in-phase-3-anxiety-trial/
- BusinessWire, “Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study” — https://www.businesswire.com/news/home/20260812579720/en/Definium-Therapeutics-Announces-Positive-Topline-Results-from-Phase-3-Voyage-Study-of-DT120-ODT-in-Generalized-Anxiety-Disorder
- STAT News, “Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial” — https://www.statnews.com/2026/08/12/definium-lsd-treatment-anxiety-study/